Cirius Therapeutics
- Biotech or pharma, therapeutic R&D
US biotech w/ Phase 3 ready oral insulin sensitizer for patients with obesity, Type 2 diabetes (T2D), MAFLD / MASH & other cardiometabolic disease, including in combination with standard of care such as GLP-1R agonists, SGLT2 inhibitors & THR-beta agonists. Inhibiting MPC, lead candidate lowers HbA1c, decreases liver fat & fibrosis, and can increase / preserve lean muscle mass & function and transform adipose tissue phenotype ("bad fat"to "good fat").
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}